ModernaThe company sold $5.9B of Covid vaccine during the first quarter. This blew out revenues and profits.

In premarket trading, the shares of the company soared more than 8 percent.

The full-year Covid sales forecast of the biotech firm was maintained by Wednesday’s company. This sales guidance was based upon signed agreements with governments. It does not take into account any U.S. orders, which could lead to a higher final figure.

Moderna reported a nearly triple increase in its first quarter vaccine sales compared with the year before. Its sales for the period ended last January, which was just a few months after Moderna first began selling shots. Spikevax, the Covid vaccine is currently available only by biotech companies.

Based on Refinitiv’s average estimates of Wall Street analysts, here’s what Moderna did.

• Adjusted EPS: $8.58 per share, vs. $5.21 expected
• Revenue6.07 Billion, as compared to $4.62 Billions expected

Moderna posted a net income of $3.66 billion for its quarter. This is three times higher than last year’s $1.2 billion.

This is an ongoing story. Keep checking back for more updates.